STOK

Stoke Therapeutics

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 3

Sell signal 2

consensus rating "Strong Buy"

Upward Gap

Revenue Beats Expectation

RSI Overbought

EPS Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About STOK

Stoke Therapeutics, Inc.

A biotech company that develops antisense oligonucleotide medicines to target RNA splicing to enhance gene expression

Industry

Biological Technology

Established Date

Invalid Date

Listing Date

06/19/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

128

Fiscal Year Ends

12-31

Website

www.stoketherapeutics.com

Security Type

Common stock

Office address

45 Wiggins Avenue, Bedford, MA 01730

Business

Introduction

Stoke Therapeutics, Inc., was founded in June 2014 and was incorporated under the laws of the State of Delaware. The company is an early-stage biopharmaceutical company that has pioneered new ways to treat the underlying causes of serious genetic diseases by precisely up-regulating protein expression. The company is developing novel antisense oligonucleotide (ASO) drugs that target ribonucleic acid or RNA and modulate precursor-messenger RNA or pre-mRNA, up-regulating protein expression to near normal levels with appropriate specificity when needed. The company uses a proprietary technology platform to target enhanced nuclear gene output, or TANGO, to design ASO to up-regulate the expression of proteins in individual patients' genes. The Company's methods are designed to deliver disease-modifying therapies to a wide range of relevant tissues, including the central nervous system, or central nervous system, eyes, kidneys and liver, in a highly precise, durable and controllable manner.

Company Financials

EPS

STOK has released its 2024 Q4 earnings. EPS was reported at -0.18, versus the expected -0.53, beating expectations. The chart below visualizes how STOK has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

STOK has released its 2024 Q4 earnings report, with revenue of 22.61M, reflecting a YoY change of 707.07%, and net profit of -10.48M, showing a YoY change of 61.12%. The Sankey diagram below clearly presents STOK’s revenue sources and cost distribution.